Symptom Dimension of Interest-Activity Indicates Need for Aripiprazole Augmentation of Escitalopram in Major Depressive Disorder: A CAN-BIND-1 Report.. J Clin Psychiatry. 81(4). 2020.
A randomized, crossover comparison of ketamine and electroconvulsive therapy for treatment of major depressive episodes: a Canadian biomarker integration network in depression (CAN-BIND) study protocol.. BMC Psychiatry. 20(1):268.. 2020.
Predicting Worsening Suicidal Ideation With Clinical Features and Peripheral Expression of Messenger RNA and MicroRNA During Antidepressant Treatment.. J Clin Psychiatry. 80(3). 2019.
MicroRNAs 146a/b-5 and 425-3p and 24-3p are markers of antidepressant response and regulate MAPK/Wnt-system genes.. Nat Commun. 8:15497.. 2017.
Integrated genome-wide methylation and expression analyses reveal functional predictors of response to antidepressants.. Transl Psychiatry. 9(1):254.. 2019.
Discovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort.. BMC Psychiatry. 16:105.. 2016.
The comparative effectiveness of electroencephalographic indices in predicting response to escitalopram therapy in depression: A pilot study.. J Affect Disord. 227:542-549.. 2017.
Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments.. Can J Psychiatry. 61(9):540-60.. 2016.
Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.. BMC Psychiatry. 14 Suppl 1:S1.. 2014.